Durvalumab and Cediranib Clinical trial - I'm in!

Please feel free to read, share your thoughts, your stories and connect with others!
NHMike
Posts: 689
Joined: Fri Jul 21, 2017 3:43 am

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby NHMike » Tue Dec 05, 2017 11:14 am

KElizabeth wrote:
NHMike wrote:Do you know your KRAS mutation?

Yes. I have KRAS mutation as well as TP53 and APC.


I think that you're the first person that I've run into here with multiple mutations and these are in multiple genes as well.

TP53 and APC are supposed to regulate cell growth and prevent tumors.

I hope that your doctors can come up with something.
6/23/17: ER rectal bleeding; Colonoscopy+Biopsy
7/13: Stage 3B rectal cancer. T3, N1b, M0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6 mm, 5 x 5 mm
7/31-9/8: Xeloda 3,400 mg/day+radiation
7/5: CEA 2.7; 8/16: 1.9; 9/8: 1.8. 11/30: 0.6
MSS, KRAS G12D
10/6: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 mm (-75%), 5 x 3 mm (-40%). 5.1 CM from AV
10/30: Surgery: LAR, Temp Ileostomy
Path report: Tumor regression grade: 0 (complete response).

boswind
Posts: 32
Joined: Fri Apr 11, 2014 12:04 pm

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby boswind » Tue Dec 05, 2017 11:32 am

Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1
01.24.2014 Male, DX @54 Rectosigmoid Cancer, MRI: T3N0M0
03.19.2014 Completed 5-week Radia+Xeloda
05.07.2014 Had surgery to remove 13cm sigmoid-colon and rectum.
02.25.2015 PET/CT/MRI scans show liver mets and L4 Spine involvement.
MSS, KRAS wild type, BRAF wild type
Mar 2015 - Aug 2015, folfox + Avastin
Aug 2015 - Jul 2017, 5FU + leucovorin + Avastin for Maintainance
Jul 2017 - Present, folfuri + Avastin
Current CEA: 5.6
Total over 50 rounds of chemo treatment received

NHMike
Posts: 689
Joined: Fri Jul 21, 2017 3:43 am

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby NHMike » Tue Dec 05, 2017 12:41 pm

boswind wrote:Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1


That's a fascinating approach. If I'm reading it correctly, it creates a bridge-molecule between T-Cells and the cell surface if CEA is highly expressed (the same CEA in the blood tests that we get).
6/23/17: ER rectal bleeding; Colonoscopy+Biopsy
7/13: Stage 3B rectal cancer. T3, N1b, M0. 5.2 x 4.5 x 4.3 cm. Lymphs: 6 x 4 mm, 8 x 6 mm, 5 x 5 mm
7/31-9/8: Xeloda 3,400 mg/day+radiation
7/5: CEA 2.7; 8/16: 1.9; 9/8: 1.8. 11/30: 0.6
MSS, KRAS G12D
10/6: 2.7 x 2.2 x 1.6 cm (-90%). Lymphs: 3 x 3 mm (-62.5%), 4 x 3 mm (-75%), 5 x 3 mm (-40%). 5.1 CM from AV
10/30: Surgery: LAR, Temp Ileostomy
Path report: Tumor regression grade: 0 (complete response).

Steph20021
Posts: 503
Joined: Sat Dec 27, 2014 4:58 pm
Location: Ontario, Canada

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby Steph20021 » Tue Dec 05, 2017 3:02 pm

I hope you get a new plan B trial very soon. I am sorry the last one didn’t help :(
DX 1/31/14 @ 33- SPS-T4a(invades visceral peri), N2a(6/106 LN), M1a(ovary) (Stage 4a) MSS
2/1/14-subtotal col, lost R ovary, temp ileo
3/14-9/14- folfox; sepsis
11/14-CT/PET: L ovary met, pelvic met, (?)ghost liver met(?)
12/14-folfiri -13 rds kept me stable from 3/15-6/15
8/15-HIPEC, hysterectomy et al, 2nd temp ileo, NED?
09/15- cea 0.9
05/16- recurrence in abdo wall and lymph nodes
Jan/17- pulmonary embolism
Feb/17- 1 wk radiation to abdo wall
Currently stable suce Aug/16- on folfiri

KElizabeth
Posts: 390
Joined: Sat Oct 31, 2015 12:41 pm
Facebook Username: KElizabeth
Location: Omaha

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby KElizabeth » Mon Dec 11, 2017 5:53 pm

NHMike wrote:
KElizabeth wrote:
NHMike wrote:Do you know your KRAS mutation?

Yes. I have KRAS mutation as well as TP53 and APC.


I think that you're the first person that I've run into here with multiple mutations and these are in multiple genes as well.

TP53 and APC are supposed to regulate cell growth and prevent tumors.

I hope that your doctors can come up with something.

I was not aware that there was any rarity in tp53 or APC. I thought they were all common mutations.
Female age 38- ,2 teens.
Colon Cancer - DX March 2013
Age 34 at DX - Stage III B
Resection surgery -May 2013
FOLFOX - June, 2013 to Sept, 2013
5FU plus leukavorin Sept, 2013 to Dec, 2013
METs liver and lungs discovered Sept, 2015
KRAS - MSS
FOLFIRI plus Avastin - Sept, 2015 - July 2017
Durvalumab and Cediranib Sept 2017 -current
CEA at recurrence:10.1/august, 2015
CEA: 1.9 February, 2016
CEA: 16.4 March 2017
CEA: 90.1 October 2017

KElizabeth
Posts: 390
Joined: Sat Oct 31, 2015 12:41 pm
Facebook Username: KElizabeth
Location: Omaha

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby KElizabeth » Mon Dec 11, 2017 5:56 pm

NHMike wrote:
boswind wrote:Hi KElizabeth,

Sorry to know the clinical trial did not work for you.

Last week I had a conversion with my Onc. In his opinion, Roche's immunotherapy for mCRC is a good candidate for a clinical trial. Please see Roche's Investor Update dated May 18, 2017.
It states that if RO6958688 is combined with atezolizumab, the disease control is 82%:
18% partial response
64% stable disease
https://www.roche.com/investors/updates ... -05-18.htm

Currently Roche have phase 1 trials for there medicine in the US:
https://clinicaltrials.gov/ct2/show/NCT ... =ab&rank=1


That's a fascinating approach. If I'm reading it correctly, it creates a bridge-molecule between T-Cells and the cell surface if CEA is highly expressed (the same CEA in the blood tests that we get).

Thank you. I'll check it out.
Female age 38- ,2 teens.
Colon Cancer - DX March 2013
Age 34 at DX - Stage III B
Resection surgery -May 2013
FOLFOX - June, 2013 to Sept, 2013
5FU plus leukavorin Sept, 2013 to Dec, 2013
METs liver and lungs discovered Sept, 2015
KRAS - MSS
FOLFIRI plus Avastin - Sept, 2015 - July 2017
Durvalumab and Cediranib Sept 2017 -current
CEA at recurrence:10.1/august, 2015
CEA: 1.9 February, 2016
CEA: 16.4 March 2017
CEA: 90.1 October 2017

Achilles Torn
Posts: 90
Joined: Fri Dec 16, 2016 2:41 pm

Re: Durvalumab and Cediranib Clinical trial - I'm in!

Postby Achilles Torn » Mon Dec 11, 2017 7:13 pm

I was not aware that there was any rarity in tp53 or APC. I thought they were all common mutations.


From everything I have read you are right. TP53 and APC are common.....and almost everyone with stage 4 CRC has more than one mutation. I think there might be confusion as many standard panels only test for ones with known clinical significance (such as KRAS, BRAF) like my cancer agency. That panel came back negative for about 50 mutations. But my follow up Foundation One report revealed those in my signature.

I’m sorry to hear about your current trial. There are lots of options still out there and I hope you find the right one.

AT
40 yo Male. BC Canada. Sigmoid Colectomy Dec. 2016
Pathology T3N2bM1 19 of 24 Nodes Positive + tumour deposits
PET scan - Para-Aortic and Iliac Lymph node spread. Stage VI.
Moderately differentiated. MSS. KRAS/BRAF Wild.
Mutations: TP53, ERBB4, MLL3, PDCD1LG2, PRKDC, SMAD3
FOLFOX Commenced Jan 9/2017 - Avastin(Bev) added after round 1.
June 2017 Dose Reduction on Round 11 due to Neuropathy.
Good PET Scan July 2017 - on maintenance 5FU/Bev every 2 weeks until progression.


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: Achilles Torn, Bing [Bot], Google [Bot] and 61 guests